You are here:Home-Inhibitors & Agonists-Antibiotics and Antivirals-HCV

Request The Product List ofHCV HCV

Cat. No. Product Name CAS No. Information
PC-63383

GSK-2878175

1423007-82-2

GSK-2878175 (GSK-175, GSK-175A) is a potent, pan-genotypic, second generation HCV NS5B polymerase inhibitor with EC50 of 0.4-9.7 nM; exhibited low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons, displayed a 60-63 h half-life and a robust decrease in viral RNA levels in HCV infected patients relative to GSK5852.

HCV Infection

Phase 2 Clinical

PC-61440

Voxilaprevir

1535212-07-7

Voxilaprevir (GS-9857) is a potent HCV NS3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir for treatment of HCV infection.

HCV Infection

Phase 2 Clinical

PC-60952

Deleobuvir

863884-77-9

Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients.

HCV Infection

Phase 3 Clinical

PC-60428

GSK-2485852

1331942-30-3

GSK-2485852 (GSK2485852, GSK5852) is a highly potent, selective HCV NS5B polymerase inhibitor with IC50 of 3.0 and 1.6 nM for HCV genotypes 1a and 1b in replicon assay, respectively; displays an excellent resistance profile and shows a <5-fold potency loss across the clinically important NS5B resistance mutations P495L, M423T, C316Y, and Y448H; targets NNI palm site 2 of NS5B and inhibits all HCV genotypes.

HCV Infection

Phase 1 Clinical

PC-35585

Cyclophilin inhibitor C31

Cyclophilin inhibitor C31 (SMCypI C31) is a small-molecule cyclophilin (CypA) inhibitor (SMCypI) with PPIase inhibition IC50 of 0.1 uM, displays anti-HCV activity (HCV Gt1b replicon EC50=0.4 uM) and disrupts the CypA-NS5A interaction; exerts at least additive antiviral effects when combined with the NS5A inhibitor ledipasvir and is fully active against ledipasvir-resistant viruses; also inhibits the replication of other members of the Flaviviridae family (DENV EC50=7.3 uM), YFV EC50, 27.2 uM, and ZIKV EC50=48.0 uM), without significant cytotoxicity.
PC-35444

Coblopasvir

1312608-46-0 Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.

HCV Infection

Phase 3 Clinical

PC-35056

Ciluprevir

300832-84-2 Ciluprevir (BILN2061) is a potent HCV NS3/4A protease inhibitor with Ki of 0.66 and 0.30 nM for NS3-NS4A protease of HCV 1b and HCV 1a, respectively; inhibits the replication of HCV replicon 1b and 1a with IC50 of 3 nM and 4 nM, respectively.

HCV Infection

Phase 2 Discontinued

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com